Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus docetaxel versus placebo plus docetaxel in previously treated advanced urothelial carcinoma
2014-003655-66Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Ramucirumab plus docetaxel with Placebo plus docetaxel (2 arms). Primary endpoint: progression-free survival. Started Mar 2015; status: completed.
02
Drugs
ramucirumabdocetaxel
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2014-003655-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003655-66.